20162017201820192020202120222023Billable/Specific Code
- D47.4 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM D47.4 became effective on October 1, 2022.
- This is the American ICD-10-CM version of D47.4 – other international versions of ICD-10 D47.4 may differ.
ICD-10-CM D47.4 is grouped within Diagnostic Related Group(s):
- 814 Reticuloendothelial and immunity disorders with mcc
- 815 Reticuloendothelial and immunity disorders with cc
- 816 Reticuloendothelial and immunity disorders without cc/mcc
Applicable To
- Chronic idiopathic myelofibrosis
- Myelofibrosis (idiopathic) (with myeloid metaplasia)
- Myelosclerosis (megakaryocytic) with myeloid metaplasia
- Secondary myelofibrosis in myeloproliferative disease
Type 1 Excludes
- acute myelofibrosis (C94.4-)
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2016 (effective 10/1/2015): No change
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
Diagnosis Index entries containing back-references to D47.4:
- with myeloid metaplasia > Myelofibrosis D75.81
- idiopathic (chronic) > Myelofibrosis D75.81
- in myeloproliferative disease > secondary D75.81
- with myeloid metaplasia > Myelosclerosis D75.89
- megakaryocytic > Myelosclerosis D75.89
- with myeloid metaplasia > megakaryocytic D47.4
